Table 2 BII Scores for subjects with GAQ Global Ratings of "Improved" versus "Not improved" at End-of-study Visit
From: Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies
Study 1 | ||||||
|---|---|---|---|---|---|---|
| Â | Â | 25th Percentile | Median | 75th Percentile | Mean | SD |
Improved | Baseline | 5.00 | 7.00 | 8.00 | 6.50 | 2.81 |
(n = 121) | End-of-Study | 1.00 | 3.00 | 5.00 | 3.08 | 2.64 |
Not improved | Baseline | 4.00 | 6.00 | 8.00 | 5.91 | 2.80 |
(n = 137) | End-of-Study | 3.00 | 5.00 | 6.00 | 4.81 | 2.72 |
Study 2 | ||||||
| Â | Â | 25 th Percentile | Median | 75th Percentile | Mean | SD |
Improved | Baseline | 4.00 | 6.00 | 8.00 | 5.74 | 2.98 |
(n = 608) | End-of-Study | 1.00 | 2.00 | 4.00 | 2.87 | 2.55 |
Not improved | Baseline | 4.00 | 6.00 | 8.00 | 5.94 | 3.00 |
(n = 283) | End-of-Study | 3.00 | 5.00 | 7.00 | 5.11 | 3.08 |